July 8, 2020
Financing co-led by Ysios Capital and INKEF Capital, joined by Lundbeckfonden Ventures, LSP, and existing investors BioGeneration Ventures and InnovationQuarter • Proceeds to be used to achieve clinical proof of concept for lead compound, VMX-C001, advance program to registrational studies, accelerate manufacturing trajectory towards commercial scale, and advance the discovery platform program Leiden, The Netherlands,...
With a total of EUR 32 million in Series B investment, Dutch VarmX can progress to the next phase of development of its drug candidate VMX-C001 – and Lundbeckfonden Ventures is one of the participating investors. Many people at risk of thrombosis take anticoagulants known as factor Xa inhibitors. However, these drugs can result in...


DNA analysis of 442 Viking skeletons rewrites the story of Viking culture
16. September 2020
Hope that a brain injection could cure type 2 diabetes
7. September 2020
Maude has become the stereotypical migraine patient – but it’s not quite the true picture
31. July 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge